KR20180135012A - 심혈관 병태에서의 세마글루타이드 - Google Patents

심혈관 병태에서의 세마글루타이드 Download PDF

Info

Publication number
KR20180135012A
KR20180135012A KR1020187033310A KR20187033310A KR20180135012A KR 20180135012 A KR20180135012 A KR 20180135012A KR 1020187033310 A KR1020187033310 A KR 1020187033310A KR 20187033310 A KR20187033310 A KR 20187033310A KR 20180135012 A KR20180135012 A KR 20180135012A
Authority
KR
South Korea
Prior art keywords
mace
fatal
semaglutide
subject
placebo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187033310A
Other languages
English (en)
Korean (ko)
Inventor
올루프 크리스티안 호이베르그 한센
Original Assignee
노보 노르디스크 에이/에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58668875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20180135012(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노보 노르디스크 에이/에스 filed Critical 노보 노르디스크 에이/에스
Priority to KR1020227036550A priority Critical patent/KR102778218B1/ko
Publication of KR20180135012A publication Critical patent/KR20180135012A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
KR1020187033310A 2016-04-28 2017-04-28 심혈관 병태에서의 세마글루타이드 Ceased KR20180135012A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227036550A KR102778218B1 (ko) 2016-04-28 2017-04-28 심혈관 병태에서의 세마글루타이드

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16167458.5 2016-04-28
EP16167458 2016-04-28
EP16188262.6 2016-09-12
EP16188262 2016-09-12
PCT/EP2017/060160 WO2017186896A1 (en) 2016-04-28 2017-04-28 Semaglutide in cardiovascular conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227036550A Division KR102778218B1 (ko) 2016-04-28 2017-04-28 심혈관 병태에서의 세마글루타이드

Publications (1)

Publication Number Publication Date
KR20180135012A true KR20180135012A (ko) 2018-12-19

Family

ID=58668875

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020187033310A Ceased KR20180135012A (ko) 2016-04-28 2017-04-28 심혈관 병태에서의 세마글루타이드
KR1020257007151A Pending KR20250038818A (ko) 2016-04-28 2017-04-28 심혈관 병태에서의 세마글루타이드
KR1020227036550A Active KR102778218B1 (ko) 2016-04-28 2017-04-28 심혈관 병태에서의 세마글루타이드

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020257007151A Pending KR20250038818A (ko) 2016-04-28 2017-04-28 심혈관 병태에서의 세마글루타이드
KR1020227036550A Active KR102778218B1 (ko) 2016-04-28 2017-04-28 심혈관 병태에서의 세마글루타이드

Country Status (24)

Country Link
US (3) US12569543B2 (https=)
EP (1) EP3448416B1 (https=)
JP (1) JP7221694B2 (https=)
KR (3) KR20180135012A (https=)
CN (1) CN109069589B (https=)
AU (2) AU2017256774B2 (https=)
BR (1) BR112018072020A2 (https=)
CA (1) CA3022535A1 (https=)
CL (1) CL2018003045A1 (https=)
DK (1) DK3448416T3 (https=)
ES (1) ES2928007T3 (https=)
HR (1) HRP20221150T1 (https=)
HU (1) HUE060040T2 (https=)
IL (1) IL262390B1 (https=)
MA (1) MA44762A (https=)
MX (1) MX2018012700A (https=)
MY (1) MY202967A (https=)
PH (1) PH12018502274B1 (https=)
PL (1) PL3448416T3 (https=)
RS (1) RS63630B1 (https=)
RU (1) RU2768283C2 (https=)
SI (1) SI3448416T1 (https=)
WO (1) WO2017186896A1 (https=)
ZA (2) ZA202507394B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7221694B2 (ja) 2016-04-28 2023-02-14 ノヴォ ノルディスク アー／エス 心血管状態におけるセマグルチド
HRP20240485T1 (hr) 2017-08-24 2024-07-05 Novo Nordisk A/S Pripravci glp-1 i njihova upotreba
HRP20230929T1 (hr) * 2018-10-26 2023-11-24 Novo Nordisk A/S Stabilni pripravci semaglutida i njihova upotreba
CN113194929B (zh) * 2018-12-21 2022-12-09 诺和诺德股份有限公司 Glp-1肽的喷雾干燥工艺
PE20230819A1 (es) * 2020-02-18 2023-05-19 Novo Nordisk As Composiciones y usos de glp-1
CN114699510B (zh) * 2021-12-29 2024-07-16 浙江湃肽生物有限公司 一种司美格鲁肽微针阵列及其制备方法
AU2023285400A1 (en) * 2022-06-08 2024-12-05 Zydus Lifesciences Limited Reusable multi-dose, variable dose, single pen injector for type 2 diabetes and weight management
CN117462654A (zh) * 2023-09-28 2024-01-30 武汉大学人民医院（湖北省人民医院） 司美格鲁肽在制备预防或治疗心肌重构的药物中的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002316811A1 (en) * 2001-06-28 2003-03-03 Novo Nordisk A/S Stable formulation of modified glp-1
WO2003084563A1 (en) * 2002-04-04 2003-10-16 Novo Nordisk A/S Glp-1 agonist and cardiovascular complications
TR201906789T4 (tr) 2003-11-20 2019-05-21 Novo Nordisk As Üretim ve enjeksiyon cihazlarında kullanım için en uygun olan propilen glikol ihtiva eden peptit formülasyonları.
TWI372629B (en) * 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
JP5662453B2 (ja) 2009-10-02 2015-01-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物の治療上の使用
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
CA3070513C (en) * 2010-05-05 2023-01-03 Boehringer Ingelheim International Gmbh A dpp-4 inhibitor for use in treatment of skin-alterations or necrosis
KR20130093012A (ko) 2010-06-24 2013-08-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
MX377589B (es) * 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
US20130035281A1 (en) * 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
EP2753642B8 (en) 2011-09-06 2017-12-13 Novo Nordisk A/S Glp-1 derivatives
US20130172244A1 (en) 2011-12-29 2013-07-04 Thomas Klein Subcutaneous therapeutic use of dpp-4 inhibitor
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013171166A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
JP6374862B2 (ja) 2012-05-24 2018-08-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 自己免疫性糖尿病、特に、ｌａｄａの治療に使用するためのｄｐｐ−４阻害剤としてのキサンチン誘導体
US20150290294A1 (en) 2012-11-02 2015-10-15 Mansoor Husain Methods for inhibiting platelet aggregation using glp-1 receptor agonists
WO2014124860A1 (en) 2013-02-14 2014-08-21 Boehringer Ingelheim International Gmbh Specific pde4b-inhibitors for the treatment of diabetes mellitus
EP2968344A1 (en) 2013-03-15 2016-01-20 Boehringer Ingelheim International GmbH Use of linagliptin in cardio- and renoprotective antidiabetic therapy
MX369818B (es) * 2013-11-15 2019-11-22 Novo Nordisk As Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
US10894054B2 (en) 2015-04-07 2021-01-19 Intercept Pharmaceuticals, Inc. FXR agonist compositions for combination therapy
US9968659B2 (en) 2016-03-04 2018-05-15 Novo Nordisk A/S Liraglutide in cardiovascular conditions
JP7221694B2 (ja) * 2016-04-28 2023-02-14 ノヴォ ノルディスク アー／エス 心血管状態におけるセマグルチド

Also Published As

Publication number Publication date
IL262390B1 (en) 2023-05-01
PL3448416T3 (pl) 2022-11-07
KR102778218B1 (ko) 2025-03-10
US20250288649A1 (en) 2025-09-18
PH12018502274A1 (en) 2019-09-09
IL262390A (en) 2018-12-31
AU2017256774B2 (en) 2024-07-11
KR20250038818A (ko) 2025-03-19
ES2928007T3 (es) 2022-11-14
AU2017256774A1 (en) 2018-11-01
JP2019514925A (ja) 2019-06-06
JP7221694B2 (ja) 2023-02-14
EP3448416B1 (en) 2022-08-10
EP3448416A1 (en) 2019-03-06
HUE060040T2 (hu) 2023-01-28
CA3022535A1 (en) 2017-11-02
RU2018140900A (ru) 2020-05-28
WO2017186896A1 (en) 2017-11-02
ZA202507395B (en) 2025-09-25
HRP20221150T1 (hr) 2022-11-25
AU2024227113A1 (en) 2024-10-31
US20250262281A1 (en) 2025-08-21
RU2768283C2 (ru) 2022-03-23
RS63630B1 (sr) 2022-10-31
US20190134162A1 (en) 2019-05-09
ZA202507394B (en) 2025-09-25
CN109069589B (zh) 2022-09-06
BR112018072020A2 (pt) 2019-02-12
KR20220147712A (ko) 2022-11-03
SI3448416T1 (sl) 2022-10-28
MA44762A (fr) 2019-03-06
US12569543B2 (en) 2026-03-10
PH12018502274B1 (en) 2024-02-28
CL2018003045A1 (es) 2018-12-14
MY202967A (en) 2024-05-31
RU2018140900A3 (https=) 2020-09-28
CN109069589A (zh) 2018-12-21
MX2018012700A (es) 2019-01-30
DK3448416T3 (da) 2022-10-03

Similar Documents

Publication Publication Date Title
KR102778218B1 (ko) 심혈관 병태에서의 세마글루타이드
AU2024201937A1 (en) Liraglutide in cardiovascular conditions
CN110022935A (zh) 用于心血管病况的德谷胰岛素
WO2017149105A1 (en) Liraglutide in renal conditions
WO2017149109A1 (en) Liraglutide in diabetic foot ulcer
HK1261741B (en) Semaglutide in cardiovascular conditions
HK1261741A1 (en) Semaglutide in cardiovascular conditions
BR122025010585A2 (pt) Uso de semaglutida para reduzir o risco de um evento cardiovascular adverso maior (mace) em indivíduos com diabetes mellitus tipo 2 e alto risco cardiovascular
HK1259166A1 (en) Liraglutide in cardiovascular conditions
HK1259166B (en) Liraglutide in cardiovascular conditions

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20181116

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200408

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210926

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220407

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210926

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20220407

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20220124

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20220620

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20220530

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20220407

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20220124

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20210926

X601 Decision of rejection after re-examination
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20221020